Authors : Dr. Hema Manogna Narne; Dr. B. Thangabalan; Jaya Lakshmi Bellemkonda; Padma Sri Sambravu; Karimunnisa Dudekula; Nitya Sri Prathuri; Snehitha Onteru; Vara Lakshmi Sanikommu; Afifa Nargees Shaik

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/4ccmxy4t

Scribd : https://tinyurl.com/4uryaj74

DOI : https://doi.org/10.38124/ijisrt/25aug905

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Hepatocellular carcinoma (HCC) remains one of the most common and deadly cancers globally. Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and a leading cause of cancer-related mortality worldwide, particularly in regions with high prevalence of viral hepatitis. Liver transplantation (LT) offers a curative option for select HCC patients by treating both the tumor and underlying liver disease. Deceased donor liver transplantation (DDLT) has traditionally been the gold standard; however, its effectiveness is limited by organ shortages, long waitlist times, and the risk of tumor progression beyond transplant criteria. Living donor liver transplantation (LDLT) has emerged as a viable alternative that can significantly reduce wait times, particularly in regions with limited access to deceased donor organs. While LDLT offers logistical and timing advantages, concerns remain regarding possible differences in long-term survival, recurrence risk, and the impact of partial grafts on tumor biology. A direct comparison of LDLT and DDLT outcomes in HCC patients remains critical to informing transplant decision-making. To compare overall survival (OS), intention-to-treat overall survival (ITT-OS), disease-free survival (DFS), and recurrence rates in HCC patients undergoing LDLT versus DDLT.

Keywords : Hepatocellular Carcinoma, Liver Transplantation, LDLT, DDLT, Meta-Analysis, Tumor Recurrence, Survival Outcomes.

References :

1. J.M. Llovet, R.K. Kelley, A. Villanueva, A. Singal, P.R. Pikarsky, S. Roayaie, R.S. Schwartz, and J. Sherman, "Hepatocellular carcinoma," Nat. Rev. Dis. Primers, vol. 7, p. 6, 2021.
2. H.B. El-Serag, "Hepatocellular carcinoma," N. Engl. J. Med., vol. 365, no. 12, pp. 1118–1127, 2011.
3. J.C. Nault and A. Villanueva, "Biomarkers for hepatobiliary cancers," Hepatology, vol. 73, Suppl. 1, pp. 115–127, 2021.
4. J. Bruix and M. Sherman, "Management of hepatocellular carcinoma: an update," Hepatology, vol. 53, no. 3, pp. 1020–1022, 2011.
5. European Association for the Study of the Liver, "EASL clinical practice guidelines: Management of hepatocellular carcinoma," J. Hepatol., vol. 69, no. 1, pp. 182–236, 2018.
6. M. Reig, A. Forner, J. Rimola, A. Ferrer-Fàbrega, F. Burrel, M. Garcia-Criado, and J. Bruix, "BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update," J. Hepatol., vol. 76, no. 3, pp. 681–693, 2022.
7. A. Vogel, T.F. Saborowski, F. Llovet, T. Finn, and A. Vogel, "Systemic treatment of hepatocellular carcinoma: past, present and future," Nat. Rev. Gastroenterol. Hepatol., vol. 17, no. 10, pp. 665–681, 2020.
8. A.G. Singal, A. Lampertico, and A.M. Nahon, "AASLD practice guidance on surveillance for hepatocellular carcinoma," Hepatology, vol. 67, no. 1, pp. 358–380, 2018.
9. A. Forner, M. Reig, and J. Bruix, "Hepatocellular carcinoma," Lancet, vol. 391, no. 10127, pp. 1301–1314, 2018.
10. P. Khetrapal, R.S. Goodman, N. Grewal, S. Zhu, Y. Wang, and J. Zhang, "Next-generation precision medicine approaches in hepatocellular carcinoma," Cancer Cell, vol. 41, no. 4, pp. 550–570.e7, 2023.
11. R.M. Ghobrial, K.A. Freise, J. Trotter, C. Tong, R. Ojo, and A.J. Ascher, "Donor morbidity after living donation for liver transplantation," Gastroenterology, vol. 135, no. 2, pp. 468–476, August 2008.
12. C.M. Lo, "Deceased and living donor liver transplantation in adults," Hepatol. Int., vol. 12, no. 5, pp. 440–450, September 2018.
13. C.L. Chen, C.H. Cheng, S.H. Chen, H. Chiang, and T.Y. Lee, "Living donor liver transplantation: 12 years of experience in a single center," Ann. Surg., vol. 243, no. 4, pp. 555–562, April 2006.
14. E.A. Pomfret, J. Leichtman, R. Freise, J.P. Emond, and L. Berg, "Adult-to-adult living donor liver transplantation: a review of the current literature for clinical outcomes, donor morbidity, and ethics," Liver Transpl., vol. 7, no. 9, pp. 851–862, September 2001.
15. A. Marcos, C. Fisher, S. Ham, M. Shaked, and J. Trotter, "Outcome of adult-to-adult living donor liver transplantation using right lobe grafts: a report of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL)," Ann. Surg., vol. 242, no. 3, pp. 376–386, September 2005.
16. S.G. Lee, Y. Hwang, J.M. Kim, and Y.S. Park, "Outcomes of living donor liver transplantation for patients with hepatocellular carcinoma beyond Milan and UCSF criteria," Ann. Surg., vol. 260, no. 5, pp. 930–939, November 2014.
17. F.Y. Yao, C. Bass, R.M. Ascher, N. Roberts, and J.P. Emond, "Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival," Hepatology, vol. 33, no. 6, pp. 1394–1403, June 2001.
18. K.H. Kim, D.H. Jung, and J.H. Park, "Laparoscopic versus open right hepatectomy in living donors: a propensity score–matched comparison," Ann. Surg., vol. 263, no. 4, pp. 745–750, April 2016.
19. R.H. Wiesner, M. Edwards, and S. Freeman, "MELD and allocation of donor livers for transplantation," Liver Transpl., vol. 9, no. 1, pp. 3–6, January 2003.
20. W.R. Kim, S. Feng, A. Lake, and J. Roberts, "OPTN/SRTR 2017 annual data report: Liver," Am. J. Transplant., vol. 19, Suppl. 2, pp. 184–283, 2019.
21. V. Mazzaferro, E. Regalia, R. Doci, P. Andreola, and L. Pulvirenti, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis," N. Engl. J. Med., vol. 334, no. 11, pp. 693–699, March 1996.

22. P.S. Kamath, R.H. Wiesner, and M. Malinchoc, "A model to predict survival in patients with end-stage liver disease," Hepatology, vol. 33, no. 2, pp. 464–470, February 2001.
23. T.E. Starzl, J. Fung, and A. Tzakis, "Liver transplantation: a 25-year perspective," Surg. Gynecol. Obstet., vol. 155, no. 3, pp. 353–372, 1982.
24. R. Adam, J. Karam, and O. Karam, "Evolution of indications and results of liver transplantation in Europe," Liver Transpl., vol. 18, Suppl. 2, pp. S5–S23, December 2012.
25. R.M. Merion, M.R. Wolfe, and J. Dykstra, "The survival benefit of liver transplantation," Am. J. Transplant., vol. 5, no. 2, pp. 307–313, February 2005.
26. S. Feng, J. Goodrich, and J. Bragg-Gresham, "Characteristics associated with liver graft failure: the concept of a donor risk index," Am. J. Transplant., vol. 6, no. 4, pp. 783–790, April 2006.
27. C.M. Lo, K.H. Fan, and C.H. Liu, "Living donor versus deceased donor liver transplantation for hepatocellular carcinoma: a matched analysis," Ann. Surg., vol. 239, no. 6, pp. 850–857, June 2004.
28. V. Mazzaferro, E. Regalia, and R. Doci, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis," N. Engl. J. Med., vol. 334, no. 11, pp. 693–699, March 1996.
29. F.Y. Yao, R.M. Bass, and N.F. Roberts, "Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival," Hepatology, vol. 33, no. 6, pp. 1394–1403, June 2001.
30. R.B. Freeman Jr., D. Gish, and S. Harper, "Liver allocation for hepatocellular carcinoma: implications of the MELD exception policy," Liver Transpl., vol. 12, Suppl. 2, pp. S13–S18, November 2006.
31. J.M. Llovet and J. Bruix, "Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival," J. Hepatol., vol. 39, no. 6, pp. 881–883, December 2003.
32. V. Mazzaferro, P. Bhoori, and M. Sposito, "Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis," Lancet Oncol., vol. 10, no. 1, pp. 35–43, January 2009.
33. V. Mazzaferro, P. Bhoori, and L. Pulvirenti, "Expanded criteria for liver transplantation in hepatocellular carcinoma: historical perspectives and current status," Liver Transpl., vol. 17, Suppl. 2, pp. S33–S36, April 2011.
34. T. Decaens, J. Roudot-Thoraval, and E. Hadj, "Impact of tumour differentiation to select patients before liver transplantation for hepatocellular carcinoma," Liver Transpl., vol. 15, no. 4, pp. 526–535, April 2009.
35. A. Vitale, L. Volk, D. Forti, and A. Burra, "Utility-based selection for liver transplantation in hepatocellular carcinoma: beyond the Milan criteria," World J. Gastroenterol., vol. 19, no. 23, pp. 3455–3460, June 2013.